Elsevier

Vaccine

Volume 34, Issue 29, 17 June 2016, Pages 3350-3355
Vaccine

Continuous active surveillance of adverse events following immunisation using SMS technology

https://doi.org/10.1016/j.vaccine.2016.05.015Get rights and content

Abstract

Introduction

On-going post-licensure surveillance of adverse events following immunisation (AEFI) is critical to detecting and responding to potentially serious adverse events in a timely manner. SmartVax is a vaccine safety monitoring tool that uses automated data extraction from existing practice management software and short message service (SMS) technology to follow-up vaccinees in real-time. We report on childhood vaccine safety surveillance using SmartVax at a medical practice in Perth, Western Australia.

Methods

Parents of all children under age five years who were vaccinated according to the Australian National Immunisation Schedule between November 2011 and June 2015 were sent an SMS three days post administration to enquire whether the child had experienced a suspected vaccine reaction. Affirmative replies triggered a follow-up SMS requesting details of the reaction(s) via a link to a survey that could be completed using a smartphone or the web. Rates of reported AEFI including fever, headache, fatigue, rash, vomiting, diarrhoea, rigours, seizures, and local reactions were calculated by vaccination time point.

Results

Overall, 239 (8.2%; 95% CI 7.2–9.2%) possible vaccine reactions were reported for 2897 vaccination visits over the 44 month time period. The proportion of children experiencing a possible AEFI, mostly local reactions, was significantly greater following administration of diphtheria–tetanus–pertussis–poliomyelitis vaccine at 4 years of age (77/441; 17.5%; 95% CI 13.9–21.0%) compared to the vaccinations given at 2–18 months (p < 0.001). Across all time points, local reactions and fatigue were the most frequently reported AEFI.

Conclusion

Automated SMS-based reporting can facilitate sustainable, real-time, monitoring of adverse reactions and contribute to early identification of potential vaccine safety issues.

Introduction

Post-marketing surveillance of vaccines is critical to identify potential safety issues [1], [2] as quickly as possible, so that changes in practice can occur in a timely manner. Important policy responses to safety signals identified through post-marketing surveillance include the withdrawal of the first rotavirus vaccine because of increased rates of intussusception [3], [4] and a contraindication for administering one brand of influenza vaccine to children less than 5 years of age due to the increased risk of severe febrile reactions [5].

Ongoing monitoring is also important for maintaining public confidence in the safety of vaccines. While pre-licensure safety studies are critical, they can be limited by relatively small sample sizes, may not reflect use of the vaccine outside the clinical trial setting (e.g. use with other vaccines or in alternate patient cohorts), and do not capture changes to the vaccine that may occur after licensure (e.g. annual strain changes in the influenza vaccine) [1], [2], [6]. Post-marketing vaccine safety surveillance is therefore important, however current mechanisms are mostly passive and may be unfavourably affected by underreporting, reporting biases, and the lack of accurate denominators for determining rates [7], [8]. To help address the limitations of passive surveillance, routine, active vaccine safety monitoring has recently been established in the United States [9], [10]. Here we describe ongoing efforts to develop a system for active post-marketing vaccine safety surveillance in Australia. SmartVax is a vaccine safety monitoring tool that uses automated data extraction from provider-based electronic patient records and short message service (SMS) technology to follow-up vaccinees in real-time. This report describes how SmartVax was used to establish reactogenicity profiles for paediatric vaccine combinations and assess the impact of changes to the childhood immunisation schedule.

Section snippets

Setting

In Australia, more than 70% of vaccinations are given by general practitioners (GPs) [9]. SmartVax has been used at a single GP medical practice in metropolitan Perth, the capital of Western Australia (WA), since 2011. The practice has approximately ten full-time practitioners, 21,000 active patients, and administers approximately 2000 paediatric vaccinations each year. Details on operational aspects of the SmartVax system have been previously described [11]. In brief, parents or guardians of

Results

Between November 2011 and June 2015, 1667 patients who were aged five years or under had a total of 3922 vaccination visits. Post-visit SMSs were sent to 3906/3922 (99.6%) of these patients and 2897/3906 (74.2%) SMS replies were received. Of the 1009/3906 (25.8%) patients sent an SMS who did not reply to the initial SMS, 284/1009 (28.1%) were reached through follow-up telephone calls. Post-vaccination information on possible reactions was unavailable for the remaining 725/3906 (18.6%)

Discussion

Our report on a novel vaccine safety surveillance system that uses automatically-generated SMS to actively monitor AEFI in children has three important findings: first, the participation rate by parents is high (>70%); second, the responses are timely (81% reply within 2 h); third, the program is sustainable with high rates of participation over time.

The overall rate of possible AEFI of 8.3% was within the range of AEFI reported from passive surveillance [13]. The most common reported reactions,

Conclusions

We described a system for active post-marketing vaccine safety surveillance in Western Australia that demonstrated our ability to establish reactogenicity profiles for paediatric vaccine combinations at a practice and assess the impact of changes to the childhood immunisation schedule on reported rates of AEFI. Automated SMS-based reporting can facilitate sustainable, real-time, monitoring of adverse reactions and contribute to early identification of potential vaccine safety issues.

Acknowledgements

We would like to acknowledge Ian Peters who provided technical guidance and support through the development of the tool and collection of data. We would like to thank Asha Bowen for critically reviewing early versions of the manuscript.

Authors’ contributions: DWW, SAW and PVE designed the study. DWW reviewed the literature, conducted the statistical analyses, analysed the data and wrote the initial draft of the manuscript. SAW and PVE supervised the analysis and assisted with writing the

References (21)

  • H. Czajka et al.

    A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile

    Vaccine

    (2009)
  • T. Nolan et al.

    Reactogenicity and immunogenicity of a live attenuated tetravalent measles–mumps–rubella–varicella (MMRV) vaccine

    Vaccine

    (2002)
  • World Health Organization

    Promoting safety of medicines in children

    (2007)
  • E. Woo et al.

    Vaccine safety surveillance

  • T.V. Murphy et al.

    Intussusception among infants given an oral rotavirus vaccine

    N Engl J Med

    (2001)
  • A.M. Galazka et al.

    Mumps and mumps vaccine: a global review

    Bull World Health Organ

    (1999)
  • P. Armstrong et al.

    Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine

    BMJ Open

    (2011)
  • R.T. Chen et al.

    Safety of routine childhood vaccinations. An epidemiological review

    Paediatr Drugs

    (2000)
  • W. Zhou et al.

    Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) – United States, 1991–2001

    Morb Mortal Wkly Rep Surveill Summ

    (2003)
  • M.S. Gold et al.

    Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia

    Med J Aust

    (2010)
There are more references available in the full text version of this article.

Cited by (11)

View all citing articles on Scopus
View full text